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A recent study of human somatic cells reprogrammed to a pluripotent state via somatic cell nuclear transfer
(SCNT) will undoubtedly renew interest in human egg procurement. Thus it is imperative that human SCNT
research move forward under stringent ethical standards in locales permitting directed egg donation for
stem cell research.The human somatic cell nuclear transfer
(SCNT) experiment recently published by
Noggle et al. (2011) comes at a crucial
point in our short history of stem cell
research. Noggle and colleagues have
taken amajor step toward deriving human
pluripotent stem cells via SCNT, and in
doing so have driven headfirst into a
complex scientific, regulatory, and fund-
ing environment (Noggle et al., 2011). On
the one hand, this report is a boon for
those interested in improving our under-
standing of human nuclear reprogram-
ming, especially in light of new un-
certainties surrounding human induced
pluripotent stem cells (hiPSCs). On the
other hand, the scientific momentum of
this early SCNT advance may be deceler-
ated by unfair rules governing payments
for stem cell research egg providers. In
this essay I offer my take on how we got
into this situation and how we ought to
proceed forward.
The Past Debate
Financial payments to egg providers are
restricted in stem cell guidelines issued
by the U.S. National Academy of Science
(NAS) and state funding regulations for
the California Institute for Regenerative
Medicine (CIRM). According to these poli-
cies, women who undergo hormonal in-
duction to provide eggs for stem cell
research may only receive reimburse-
ments for their out-of-pocket expenses.
Compensation—i.e., payment for their
time, effort, and inconvenience—is
prohibited.
Policymakers who drafted the NAS and
CIRM guidelines had to tackle the central
ethical controversies surrounding egg
provider compensation during a time of
great political and scientific uncertainty
in the United States. Concerns about
political backlash against embryonicstem cell (ESC) research were especially
acute during the mid-Bush era, so deci-
sion-makers at the NAS and CIRM—
many of whom had strong opinions,
whether pro or con, on the issue of
compensation—had the unenviable task
of trying to charter the least socially con-
troversial path forward for stem cell
research. Even proponents of compensa-
tion could appreciate at the time that
a firm anticompensation policy would to
help insulate their support for ESC re-
search against greater heat from critics
of these endeavors.
Added to this context was a prevalent
view that ‘‘therapeutic cloning’’ was
edging toward clinical reality, due to
the extraordinary claims being made by
Woo Suk Hwang in South Korea. Given
Hwang’s published claims and the grow-
ing hype surrounding the therapeutic
potential of stem cells, many observers
had reason to suggest that there should
be a no-compensation rule to align egg
donation for therapeutic cloning closer
to other types of therapeutic donations
such as kidney and bone marrow. Ac-
cording to this implicit analogy, there
ought to be no donor payments for human
materials of any kind that are collected in
the course of clinical treatment, since
such payments could introduce worri-
some market forces and inequities in the
distribution of therapeutic goods. (Unlike
research donations, payments for thera-
peutic donations are not subject to re-
search ethics board review; hence the
worry about unregulated market influ-
ences.) Ironically, one longstanding ex-
ception to this ‘‘no compensation for clin-
ical donation’’ imperative is the prevalent
American practice of compensating egg
donors for fertility treatment.
Whether it was ever correct to link
SCNT egg donor compensation to theCell Stem Cellissue of payments for therapeutic dona-
tions is neither here nor there, for in hind-
sight we now realize that human SCNT is
nowhere near direct clinical application,
and may never be. Thus, today we must
resist the temptation to take what is
essentially donation for basic research
and reframe it under a medically thera-
peutic donation model.
Basic research was the focus of the
guidelines issued by the International
Society for Stem Cell Research (ISSCR),
which took a different approach from the
NAS and CIRM on the matter of human
egg procurement. The ISSCR Guidelines
were developed in 2006 after the expo-
sure of the Hwang group’s faked re-
search, whereas the CIRM and NAS
guidelines were issued prior to this land-
mark event. When I chaired the ISSCR
Guidelines Task Force Subcommittee on
Human Materials Procurement, my sub-
committee and I deliberated for the lon-
gest time on the issue of egg provider
payment. We knew that ‘‘therapeutic
cloning’’ was not just around the corner
as had been claimed before ‘‘Hwang-
gate.’’ My subcommittee and I reasoned
unanimously that the ISSCR Guidelines
should allow international research com-
munities freedom to decide for them-
selves the contentious matter of egg pro-
vider compensation in a way that was free
from American political pressures. Ulti-
mately, the published ISSCR Guidelines
shied away from language that would
explicitly permit compensation, but in-
stead recommended more diplomatically
and generally that financial consider-
ations of any kind must not constitute an
undue inducement, and that at no time
should payments be given for the number
and quality of the research eggs them-
selves (ISSCR, 2006). Independent ethical
review was also strongly recommended9, October 7, 2011 ª2011 Elsevier Inc. 295
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ments (Daley et al., 2007).
I believe there aremany reasons to con-
tinue supporting the more flexible and
permissive approach taken in the ISSCR
Guidelines (Hyun, 2006). Every commen-
tator in the compensation debate should
be obligated to begin by acknowledging
that hormonal induction is a very burden-
some procedure for women, requiring
enormous amounts of time, discomfort,
and personal commitment. Normally, in
other areas of biomedical science, people
who provide human biological research
materials via invasive surgical procedures
are proportionately compensated for their
time, effort, and inconvenience (Crockin,
2010). In these cases, compensation is
permitted only after an ethical review
board has approved the study team’s
payment levels and recruitment practices.
Likewise, I believe women who are asked
to generate eggs directly for stem cell re-
search should be compensated just like
other biological materials providers, with
all the same human protections in place
to prevent their exploitation and the like.
My position here is grounded in an
appeal to fairness and ethical consis-
tency. If reimbursements for oocyte pro-
viders are ethically justified, then so is
compensation, for both are founded on
the same philosophical aim of counter-
balancing personal losses endured by
the research volunteer. Stem cell re-
search guidelines in the U.S. permit reim-
bursements for out-of-pocket expenses
because it would be grossly unfair, not
to mention detrimental to recruitment
efforts, not to pay back research volun-
teers for any money they had to spend
to help a study team pursue its research
goals. But if small burdens are to be
acknowledged, such as parking ex-
penses, babysitting fees, and meals in
a clinic’s cafeteria, thenwhy not very large
burdens, such as the physical pain,
discomfort, and time required by hor-
monal induction for research volunteers?
If anything, we ought always to prioritize
the recognition of larger burdens ahead
of our recognition of smaller burdens.
Research regulators and the study team
cannot give a woman back her time, nor
can they physically remove the suffering
she must endure as a research oocyte
provider. In the U.S. and in nearly all other
countries, the most widely used and
socially approved form of recognizing296 Cell Stem Cell 9, October 7, 2011 ª2011a person’s time, effort, and inconvenience
is financial compensation. In the present
context of research participation and
oversight, compensation, like reimburse-
ment, is not meant to raise a person to
a level above where she was prior to her
participation; rather, both reimbursement
and compensation are meant to acknowl-
edge what she has had to sacrifice during
the course of the research project. Com-
pensation implies a personal loss, which
others are obligated to respond to pro-
portionately. The past ethical debate
should have better appreciated this key
philosophical point—namely, that com-
pensation, like its conceptual cousin
‘‘reparation,’’ is a matter of fairness and
equitable treatment.
The New Realities
Flash forward to the present. Private
donations supported the research of
Noggle et al. consistent with the Empire
State StemCell Board’s permissive policy
on compensating egg providers for re-
search. This funding comes at the end
of a multiyear attempt by some of the
study’s researchers to recruit altruistic
egg donors in Massachusetts (Egli et al.,
2011). This lengthy ‘‘social experiment’’
had turned out to be a flat-out failure,
with only one altruistic egg donor ever
being recruited. These sustained efforts
confirmed what many of us had sus-
pected all along—that women typically
are not willing to endure hormonal in-
duction for research simply in exchange
for validated parking tickets, reimbursed
meals, and a pat on the back (Klitzman
and Sauer, 2009). What outside observers
should learn from this experience is that
we do not live in a world where our policy
choice is between altruistic egg donation
on the one hand and compensation on
the other. In the actual world, our true
alternatives are fair compensation or
a dearth of eggs for research. If we want
more SCNT research to build upon the
work of Noggle et al., we must continue
to compensate egg providers under strict
ethical guidelines.
But why should we care about
advancing human SCNT research? The
answers are both scientifically and ethi-
cally significant. While the study by
Noggle et al. produced triploid pluripotent
cells not directly translatable for clinical
applications, there are many valuable les-
sons we can learn from egg-mediatedElsevier Inc.nuclear reprogramming. For one, SCNT
could reveal faster, safer ways to repro-
gram somatic cells. The unfertilized egg
reprograms the somatic cell nucleus
within hours, whereas hiPSC reprogram-
ming occurs over days or weeks and
may generate cells with accumulated
harmful genetic and epigenetic changes
(Barrilleaux and Knoepfler, 2011). Eggs
are endowed with very high concentra-
tions of unknown proteins involved in
chromatin decondensation, DNA deme-
thylation, and transcriptional activation
of embryo genes (Jullien et al., 2011). Un-
veiling these proteins will help scientists
improve the speed and safety of direct
cellular reprogramming.
As a case in point, Shinya Yamanaka
and colleagues recently discovered that
the transcription factor Glis1 (which is en-
riched in unfertilized eggs and zygotes,
but not expressed in ESCs) can be used
to replace the tumorigenetic transcription
factor c-Myc to create hiPSCs (Maekawa
et al., 2011). In view of previous animal
SCNT studies and mouse cloning via
somatic cell chromosome transfer into
zygotes (Egli et al., 2007), Yamanaka
and colleagues reasoned that there must
be maternal transcription factors in unfer-
tilized eggs and zygotes that promote
nuclear reprogramming; and they subse-
quently identified Glis1 as one of these
factors (Maekawa et al., 2011).
As this last example highlights, stemcell
research is a collection of interrelated
activities that progresses together as a
whole. Crucially, the scientific reasons for
advancing SCNT research, when viewed
from a slightly different angle, also amount
to ethical reasons. Troubling differences
have recently been observed in gene
expression patterns between hiPSCs and
hESCs (Barrilleaux and Knoepfler, 2011).
If, with continued SCNT research, diploid
SCNT stem cells can be derived, it would
be extremely valuable to compare them
to hiPSCs and hESCs to understand key
differences in each and their implications
for the development of safer stem cell-
based clinical applications. Such valuable
knowledge cannot be gained simply by
studyingmouse SCNT, for there are major
biological differences between mouse
and human eggs. In order to attain the
subtle comparative information we need,
we must use human materials.
Unfortunately, other researchers will
not be able to use CIRM funds to study
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Noggle et al., since state regulations
prohibit CIRM funding for research on
stem cell lines derived from compensated
egg donors. Through an ironic twist of
fate, this anticompensation policy, which
may have been partially motivated by
a desire to help protect the stem cell field,
may now end up slowing down the stem
cell field’s progress toward safer clinical
applications. Nor can these SCNT stem
cells be placed on the NIH’s stem cell
registry for NIH-fundable stem cell lines,
for the separate reason that they were
derived from embryos created specifically
for research purposes. With neither CIRM
nor NIH funds available for studying
human SCNT stem cells, how are re-
searchers supposed to extend the contri-
butions of SCNT research to the entire
stem cell field?
Moving SCNT Forward Ethically
Given applicable funding restrictions in
the U.S., further SCNT research will have
to be supported by alternative funding
sources in permissive jurisdictions, such
as New York State, or in jurisdictions
abroad like the UK, where the HFEA
allows fertility clinic egg sharing for SCNT
research.
In all of these locales, it will be crucial to
maintain very high standards of research
ethics. First, we must continue to work
as hard as possible to reduce the risks
associated with hormonal induction, for
example, through further fertility research
and by frequent patient monitoring for
ovarian hyperstimulation syndrome and
other complications. Second, egg pro-
vider recruitment practices and compen-
sation levels must be approved and
closely monitored by independent human
protections committees. Compensation
levels must be held to levels appropriate
for similarly invasive procedures. And, as
with all biomedical research, women of
lower socioeconomic classes must not
be disproportionately recruited for partic-
ipation. Third, the ethical integrity of the
informed consent process for egg pro-viders must be maintained. For example,
no one must breach the informed consent
contract and use research eggs or cloned
research embryos for reproductive pur-
poses. Any violation of this informed
consent promise to egg providers ought
to be met with stiff legal penalties.
Some may worry that it would be
impossible to determine whether an offer
of compensation for time, effort, and
inconvenience might not also serve as
a financial incentive for some women to
volunteer to provide their eggs (Marshall
et al., 1999). I agree there may be no prac-
tical way to guarantee against this possi-
bility. But perhaps the potential incentiv-
izing effects of compensation are not so
objectionable, as long as the ethical stan-
dards above are attended to diligently.
Personally, I do not believe the funda-
mental ethical issue here is inducement
per se, as long as the research proposal
poses reasonable risks and is approved
by an independent human subject protec-
tions board. What we ought to be worried
about instead is the possibility of undue
inducement.
As emphasized in the ISSCR Guide-
lines, we must preserve the voluntariness
of egg provider decisions by avoiding
undue inducement. Undue inducement
is a specific threat to autonomous
decision-making in that volunteers may
become so distracted by a high offer of
compensation that they fail to fully com-
prehend the risks involved in hormonal
induction (Hyun, 2006). One of the best
ways to guard against undue inducement
(besides ethics board approval of pay-
ment levels) is by verifying volunteers’
understanding through a ‘‘teach back’’
method. Can the volunteer explain back
to the researcher and her physician all
the relevant risks and their conse-
quences? If so, then we ought to trust
her judgment and conclude that the threat
of undue inducement in her case has been
disarmed. As in all research, we must
respect a woman’s right to autonomy
and not slip into paternalistic attitudes.
Autonomous decisions to participate inCell Stem Cellethically reviewed research should be
honored if these decisions are based on
the best available information and a care-
ful consideration of the alternatives, even
if some critics may personally disagree
with the woman’s choices. Such is the
nature of respecting personal autonomy.
In conclusion, the human SCNT genie is
just starting to emerge from the bottle,
and it will be impossible to stuff it back
in or ignore it. Regulators and funders
must face up to this new reality and chal-
lenge themselves to figure out how to
compensate women fairly and empower
SCNT research to benefit the stem cell
field.
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